Here are the top Institutional holders of Black Diamond Therapeutics Inc (BDTX) shares

Black Diamond Therapeutics Inc (NASDAQ: BDTX) is 59.07% higher on its value in year-to-date trading and has touched a low of $1.22 and a high of $6.85 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The BDTX stock was last observed hovering at around $3.87 in the last trading session, with the day’s gains setting it 0.6%.

Currently trading at $4.47, the stock is 37.75% and 53.78% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.74 million and changing 15.50% at the moment leaves the stock 58.01% off its SMA200. BDTX registered 46.56% gain for a year compared to 6-month loss of 35.45%. The firm has a 200-day simple moving average (SMA200) of -$1.32.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.
Sponsored

The stock witnessed a 47.04% gain in the last 1 month and extending the period to 3 months gives it a 145.60%, and is 4.93% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 11.46% over the week and 9.10% over the month.

Black Diamond Therapeutics Inc (BDTX) has around 65 employees, a market worth around $230.83M and $0.00M in sales. Distance from 52-week low is 266.39% and -34.74% from its 52-week high. The company has generated returns on investments over the last 12 months (-53.47%).

Black Diamond Therapeutics Inc quarterly earnings per share for the current quarter are estimated at -$0.47.The EPS is expected to grow by 21.27% this year

90 institutions hold shares in Black Diamond Therapeutics Inc (BDTX), with institutional investors hold 89.46% of the company’s shares. The shares outstanding are 51.64M, and float is at 37.24M with Short Float at 9.60%. Institutions hold 87.14% of the Float.

The top institutional shareholder in the company is Bellevue Group AG with over 8.14 million shares valued at $41.09 million. The investor’s holdings represent 15.77% of the BDTX Shares outstanding. As of Jun 29, 2023, the second largest holder is NEA Management Company, LLC with 4.45 million shares valued at $22.47 million to account for 8.63% of the shares outstanding. The other top investors are RA Capital Management, L.P. which holds 3.53 million shares representing 6.84% and valued at over $17.81 million, while Artal Group S.A. holds 3.97% of the shares totaling 2.05 million with a market value of $10.33 million.

Black Diamond Therapeutics Inc (BDTX) Insider Activity

A total of 3 insider transactions have happened at Black Diamond Therapeutics Inc (BDTX) in the last six months, with sales accounting for 0 and purchases happening 3 times. The most recent transaction is an insider purchase by BIOTECH GROWTH N V, the company’s 10% Owner. SEC filings show that BIOTECH GROWTH N V bought 400,000 shares of the company’s common stock on Oct 17 at a price of $2.34 per share for a total of $0.93 million. Following the purchase, the insider now owns 8.52 million shares.

Black Diamond Therapeutics Inc disclosed in a document filed with the SEC on Jul 05 that Behbahani Ali (Director) bought a total of 1,000,000 shares of the company’s common stock. The trade occurred on Jul 05 and was made at $5.00 per share for $5.0 million. Following the transaction, the insider now directly holds 4.45 million shares of the BDTX stock.

Still, SEC filings show that on Jul 05, RA CAPITAL MANAGEMENT, L.P. (Director) acquired 935,850 shares at an average price of $5.00 for $4.68 million. The insider now directly holds 3,213,828 shares of Black Diamond Therapeutics Inc (BDTX).